Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction
Briones, Ana (Universidad Autónoma de Madrid)
Hernanz, Raquel (Universidad Rey Juan Carlos)
Garcia Redondo, Ana B. (Universidad Autónoma de Madrid)
Rodríguez, Cristina (Institut de Recerca Sant Pau)
Blanco-Colio, Luis Miguel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Val-Blasco, Almudena (Hospital Universitario La Paz (Madrid))
Alonso, María Jesús (Universidad Rey Juan Carlos)
Salaices Sanchez, Mercedes (Universidad Autónoma de Madrid)

Data:	2025
Resum:	Excessive local inflammation is a common mechanism in many cardiovascular diseases (CVDs) such as hypertension, atherosclerosis and aortic aneurysms. In endothelial cells, inflammatory cytokines such as interferons, tumour necrosis factor alpha or interleukins increase oxidative stress and contractile prostanoids and the expression of adhesion molecules that reduce nitric oxide (NO) availability and bind leucocytes, thereby impairing endothelial function. Despite this evidence, anti-inflammatory therapies are not yet indicated for the treatment of most CVD. Resolution of inflammation is mediated by a family of specialized pro-resolving mediators (SPMs) that act on cognate G protein-coupled receptors to limit immune cell infiltration and initiate tissue repair. SPMs, generated from omega-3 and omega-6 polyunsaturated fatty acids, belong to four major families: lipoxins, resolvins, protectins and maresins. SPM receptors are expressed in immune and vascular cells where they regulate important processes such as phagocytosis and polarization, production of cytokines, NO and prostacyclin, and modulation of smooth muscle cell phenotype. Growing evidence in animal models demonstrates that activation of SPM receptors can protect vascular function and structure and provide beneficial effects in various CVD. We will review recent advances in the role of inflammation and SPMs in vascular (dys)function in hypertension, atherosclerosis, and aortic aneurysms.
Ajuts:	Agencia Estatal de Investigación PID2020-116498RB-I00 Ministerio de Economía y Competitividad CB16/11/00286 Ministerio de Economía y Competitividad CB16/11/00257 Ministerio de Economía y Competitividad CB16/11/00333 European Commission 954798 Instituto de Salud Carlos III AC23_2/00044
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cardiovascular diseases ; Endothelial dysfunction ; Hypertension ; Inflammation ; Specialized proresolvin mediators
Publicat a:	Basic & Clinical Pharmacology & Toxicology, Vol. 136 Núm. 5 (May 2025) , ISSN 1742-7843

DOI: 10.1111/bcpt.70026
PMID: 40159875

10 p, 337.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats